Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fusion AntibodiesLSE:FAB 26 EV-to-EBITDA is -9.38 as of Aug. 16, 2026. GuruFocus rates LSE:FAB with a GF Score™ of 26/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 402 Biotechnology companies, Fusion Antibodies ranks worse than 248755.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fusion Antibodies's enterprise value is £13.28 Mil.
Fusion Antibodies's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was £-1.42 Mil. Therefore, Fusion Antibodies's EV-to-EBITDA for today is -9.38.
The historical rank and industry rank for Fusion Antibodies's EV-to-EBITDA or its related term are showing as below:
LSE:FAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -97.01 Med: -10.21 Max: 292.3
Current: -9.38
During the past 11 years, the highest EV-to-EBITDA of Fusion Antibodies was 292.30. The lowest was -97.01. And the median was -10.21.
LSE:FAB's EV-to-EBITDA is ranked worse than 100% of 402
companies
in the Biotechnology industry
Industry Median: 13.825
vs LSE:FAB: -9.38
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Fusion Antibodies's PE Ratio (TTM) for today is calculated as:
Fusion Antibodies's share price for today is £0.105.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was £-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Fusion Antibodies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:FAB vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Fusion Antibodies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fusion Antibodies EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fusion Antibodies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fusion Antibodies's EV-to-EBITDA falls into.
Fusion Antibodies's current Enterprise Value is £13.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fusion Antibodies's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was £-1.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fusion Antibodies (LSE:FAB) has a EV-to-EBITDA of -9.38 as of Aug. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fusion Antibodies. According to the industry distribution chart, Fusion Antibodies ranks #999999 out of 402 companies in the Biotechnology industry.
Is Fusion Antibodies' EV-to-EBITDA too high?
Fusion Antibodies' current EV-to-EBITDA is -9.38. Based on the distribution chart, Fusion Antibodies ranks #999999 out of 402 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fusion Antibodies has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fusion Antibodies ranks #999999 out of 402 companies for EV-to-EBITDA. This places Fusion Antibodies in the lower half of its industry. The industry median EV-to-EBITDA is 13.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.83, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Fusion Antibodies. For the Biotechnology industry, the median EV-to-EBITDA is 13.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fusion Antibodies's current EV-to-EBITDA is -9.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.11 — trading 162.5% above its estimated fair value. The current EV-to-EBITDA is -9.38. Fusion Antibodies' overall GF Score™ is 26/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current EV-to-EBITDA is -9.38 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?
Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued.
The current stock price of £0.11 is trading 162.5% above its estimated GF Value™ of £0.04.
GuruFocus considers Fusion Antibodies to be Significantly Overvalued.
Key valuation signals for LSE:FAB:
EV-to-EBITDA: -9.38
GF Value™: £0.04 vs. price of £0.11 (162.5% above fair value)
No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
26GF Score
Get the complete analysis for LSE:FAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:FAB has been successfully added to your 
